Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To describe efficacy, tolerability and convenience of teriflunomide treatment through the
evaluation of Participant Reported Outcomes (PROs).
Secondary Objectives:
To describe disease progression using PROs. To describe clinical outcomes (ie, treated
relapses) in teriflunomide treated participant.
To describe the change in cognition in teriflunomide treated participants. To describe safety
of teriflunomide in participant treated (based on adverse events reporting).
To describe adherence and persistence to teriflunomide treatment. To describe quality of
life, activity and leisure over the period of teriflunomide treatment.
To compare Participant Determined Disease Steps (PDDS) and Expanded Disability Status Scale
(EDSS) in assessing Multiple Sclerosis (MS) disease progression.